IBJNews

Biomet offers to acquire DePuy trauma biz for $280M

Back to TopCommentsE-mailPrintBookmark and Share

Biomet Inc. has offered to buy the trauma products business of DePuy Orthopaedics Inc. for $280 million in cash, the Warsaw-based medical device maker said on Tuesday.

DePuy, a unit of New Jersey-based Johnson & Johnson since 1998, also is based in the northern Indiana city of Warsaw.

Biomet, which designs and manufactures orthopedic products for surgical and non-surgical uses, said the deal would greatly expand its sports, extremities and trauma business. DePuy makes artificial joints and other orthopedic devices.

J&J is attempting to spin off DePuy’s trauma products business as it seeks to finalize its planned $21.3 billion acquisition of Swiss medical device maker Synthes Inc.

“We believe the divestiture will satisfy all regulatory concerns relating to the pending purchase of Synthes by Johnson & Johnson, but we will not know with certainty until the regulatory processes in the [European Union] and U.S. are completed,” J&J said in a prepared statement. “We continue to make progress in our work with antitrust authorities on the Synthes transaction.”

The European Commission opened an expanded probe last November of J&J's bid to buy Synthes in a deal that would make J&J the leader in the $5.5 billion trauma device market. The Brussels-based regulator is expected to rule on the acquisition by April 26.

Biomet’s offer to DePuy expires June 1 but could be extended under certain circumstances.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT